Study of ZG005 in Patients With Advanced Solid Tumors

NCT06927687 · tracked via the Priya Life Science China tracker

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase

Phase 2

Started

2025-06-13

Last updated

2026-04-29

Condition(s) studied

Advanced Solid Tumor

Investigational drug(s) / intervention(s)

ZG005 for Injection →

ZG005 for Injection: Recommended Phase 2 Dose (RP2D) of ZG005(20 mg/kg), intravenous infusion, once every 3 weeks.

Study summary

This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Fully understand the study and voluntarily sign the informed consent form. * Male or female 18-75 years of age; * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1; * Life expectancy ≥ 12 weeks; * Histologically or cytologically confirmed diagnosis of advanced solid tumors. Exclusion Criteria: * Medical history, computed tomography (CT) or magnetic resonance imaging (MRI) results indicate that existence of the central nervous system(CNS) metastases; * Any other malignancy within 5 years.

Primary outcome measure(s)

Objective response rate(ORR) — Up to 2 years

Trial sites (1)

Facility	City	Region	Status
Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

More Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials in China

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma Recruiting

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer Recruiting

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer Recruiting

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma Recruiting

Study of ZGGS18 in Patients With Advanced Solid Tumors Recruiting

Other trials for the same condition

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors Recruiting

Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors Active, not recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors Recruiting

Study SC-101 in Subjects With Advanced Malignancies Recruiting

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06927687 on ClinicalTrials.gov ↗ ← All trials in China